Both NHL and HD patients were then further evaluated for posttreatment changes in peripheral blood lymphocyte counts by flow cytometry and serum levels of vascular endothelial growth factor (VEGF), bFGF, and IFN‐γ by ELISA. The gene discussed is FGF2; the disease is non-Hodgkin lymphoma.